Lantheus to Host Second Quarter 2024 Earnings Conference Call and Webcast on July 31, 2024, at 8:00 a.m. Eastern Time
Lantheus Holdings (NASDAQ: LNTH) has announced its upcoming second quarter 2024 earnings conference call and webcast, scheduled for July 31, 2024, at 8:00 a.m. Eastern Time.
Rhea-AI Summary
Lantheus Holdings (NASDAQ: LNTH) has announced its upcoming second quarter 2024 earnings conference call and webcast, scheduled for July 31, 2024, at 8:00 a.m. Eastern Time. The event will provide an opportunity for stakeholders to learn about the company's financial and operating results for Q2 2024. Participants are encouraged to register online at the investor relations website, preferably fifteen minutes before the start time to avoid delays. A replay of the webcast will be available approximately two hours after completion and will remain archived on the same web page for at least 30 days.
Positive
- None.
Negative
- None.
Details
News Market Reaction – LNTH
The recorded move for LNTH in the trading session of this news was +2.80%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
BEDFORD, Mass., July 17, 2024 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH) today announced that it will host a conference call and webcast at 8:00 a.m. ET on Wednesday,
July 31, 2024, to discuss its financial and operating results for the second quarter of 2024.
To access the conference call or webcast, participants should register online at https://investor.lantheus.com/news-events/calendar-of-events. To avoid delays, we encourage participants to register fifteen minutes ahead of the scheduled start time.
A replay will be available approximately two hours after completion of the webcast and will be archived on the same web page for at least 30 days.
About Lantheus
Lantheus is the leading radiopharmaceutical-focused company, delivering life-changing science to enable clinicians to Find, Fight and Follow disease to deliver better patient outcomes. Headquartered in Massachusetts with offices in Canada and Sweden, Lantheus has been providing radiopharmaceutical solutions for more than 65 years. For more information, visit www.lantheus.com.
Contacts:
Mark Kinarney
Vice President, Investor Relations
978-671-8842
ir@lantheus.com
Melissa Downs
Senior Director, External Communications
646-975-2533
media@lantheus.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.